Comparison of Semaglutide and Lifestyle Counselling for Weight Loss Using Multi‐Site Electronic Health Records
Clinical Obesity · 2026-04 · 16 (2)
DOI: 10.1111/cob.70076 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Obesity, online erschienen am 13.03.2026. Verfasst von William J B Powell und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Health Informatics, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA. Hauptthemen laut MEDLINE: Counseling, Life Style, Obesity, Semaglutide. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Patient-Centered Outcomes Research Institute, University of Missouri.
Abstract (Originalsprache)
To evaluate the effectiveness of semaglutide compared with lifestyle counselling alone for weight loss in diabetic and non‐diabetic patients with obesity. This multi‐site, retrospective, observational study uses data from electronic health records which are part of the Greater Plains Collaborative (GPC) in a time‐to‐event analysis for comparative effectiveness. Participants were adults with obesity receiving semaglutide for a minimum of 16 weeks or lifestyle counselling with at least three sessions within the first 16 weeks. The primary outcome is incidence of 10% or greater reduction in weight from baseline. Of 3927 eligible participants, 615 were prescribed semaglutide and 3312 received lifestyle counselling. Following propensity score matching, each group (diabetic and non‐diabetic) consisted of 120 and 495 participants, respectively. Hazard ratios for 10% weight loss were significantly higher from semaglutide for non‐diabetic (1.63 [95% CI: 1.32, 2.01; p < 0.001]) and diabetic (2.45 [95% CI: 1.47, 4.09; p < 0.001]) populations. These data from our study suggest that semaglutide therapy compared with lifestyle counselling alone is more effective in achieving at least 10% weight loss. This information may be used to inform clinical practice guidelines and stimulate future research on the long‐term effectiveness of various weight loss options for individuals with obesity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical and Health Informatics, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA.
- Division of Medical Informatics, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.
- Kansas Center for Metabolism and Obesity Research, The University of Kansas Medical Center, Kansas City, Kansas, USA.
- Department of Pediatrics, University of Kansas Medical Center, Kansas City, Kansas, USA.
- Center for Children's Healthy Lifestyles & Nutrition, Kansas City, Missouri, USA.
- Departments of Medicine and Nutrition & Exercise Physiology, University of Missouri, School of Medicine, Columbia, Missouri, USA.
ORCID-Profile: William J B Powell, Bettina Mittendorfer, Xing Song
Förderung
- Patient-Centered Outcomes Research Institute
- University of Missouri
Zitieren
APA
Powell, W. J. B., Mazzotti, D. R., Herrmann, S. D., Davis, A. M., Mittendorfer, B., Bruce, J., Song, X., & Waitman, L. R. (2026). Comparison of Semaglutide and Lifestyle Counselling for Weight Loss Using Multi‐Site Electronic Health Records. Clinical Obesity, 16(2). https://doi.org/10.1111/cob.70076
Vancouver
Powell WJB, Mazzotti DR, Herrmann SD, Davis AM, Mittendorfer B, Bruce J, et al. Comparison of Semaglutide and Lifestyle Counselling for Weight Loss Using Multi‐Site Electronic Health Records. Clinical Obesity. 2026;16(2). doi:10.1111/cob.70076
BibTeX
@article{Powell2026,
author = {Powell, William J B and Mazzotti, Diego R and Herrmann, Stephen D and Davis, Ann M and Mittendorfer, Bettina and Bruce, Jared and Song, Xing and Waitman, Lemuel R},
title = {Comparison of Semaglutide and Lifestyle Counselling for Weight Loss Using Multi‐Site Electronic Health Records},
journal = {Clinical Obesity},
year = {2026},
volume = {16},
number = {2},
doi = {10.1111/cob.70076}
}
EUVIMED